Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | INSR | P06213 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | MAP2 | P11137 | 2/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13685462 | 0.88 | BRD4 (0.47) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL2199893 | 0.86 | BRD4 (0.42) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL2200493 | 0.85 | BRD4 (0.46) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL2199883 | 0.82 | CHEK1 (0.45) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL2196927 | 0.80 | CDC7 (0.54) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL2201344 | 0.79 | HTT (0.57) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL2198470 | 0.78 | BRD4 (0.47) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL2197555 | 0.77 | BRD4 (0.49) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL4348642 | 0.77 | BRD4 (0.41) | BRD4CDC7CHUKINSRMAPK8 | |
| SCHEMBL4344137 | 0.77 | BRD4 (0.43) | BRD4CDC7CHUKINSRMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | UACA, IL6, IL6ST | BRD4 497/4885CDC7 4329/4885CHUK 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.